Diabet. Med. 32, 819--828 (2015)25581456

Introduction {#dme12685-sec-0005}
============

Fasting during Ramadan, the holy month of the Islamic lunar calendar, is an obligatory practice for healthy adult Muslims. Although potentially exempt from the obligation, the majority of Muslim patients with diabetes also choose to fast. The authors of the multi‐country Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study reported that 78.7% of patients with Type 2 diabetes fasted for at least 15 days during Ramadan [1](#dme12685-bib-0001){ref-type="ref"}. Combining the EPIDIAR results with a 2010 global Muslim population estimate of 1.6 billion [2](#dme12685-bib-0002){ref-type="ref"} and an updated estimated global prevalence of Type 2 diabetes---8.3% among adults [3](#dme12685-bib-0003){ref-type="ref"}---it can be estimated that there are at least 132 million Muslims worldwide with diabetes, of whom more than 100 million may fast during Ramadan. Furthermore, economic development, and the associated decreased physical activity and high‐calorie diets, are projected to contribute to an 'obesogenic' environment in countries with large Muslim populations, increasing the number of people with diabetes. Projected population growth and epidemiological trends suggest that understanding the management of patients with diabetes who fast during Ramadan remains critical.

The EPIDIAR study also identified a need for more intensive education before fasting, for the dissemination of guidelines and for further studies assessing the impact of fasting on morbidity and mortality [1](#dme12685-bib-0001){ref-type="ref"}. Since publication of the study results, there has been increasing awareness that fasting during Ramadan represents a global medical issue, prompting the development of recommendations for the management of diabetes during Ramadan [4](#dme12685-bib-0004){ref-type="ref"}, [5](#dme12685-bib-0005){ref-type="ref"} and structured education programmes [6](#dme12685-bib-0006){ref-type="ref"}. Additionally, a collaboration of medical experts and religious scholars provided important religious guidance via a decree issued in April 2009 [7](#dme12685-bib-0007){ref-type="ref"}.

New published data, new pharmacological agents and clear religious guidance may have changed both the management and outcomes of patients with diabetes who fast during Ramadan. In keeping with the recommendations of the EPIDIAR study group, we conducted a multi‐country study to describe the characteristics, and multiple approaches to the management of patients with diabetes who fasted during Ramadan 2010. The primary objective was to evaluate the percentage of patients who had a change in diabetes treatment regimen before and during Ramadan in 2010/1431.

Study design and methods {#dme12685-sec-0006}
========================

The Multi‐Country Retrospective Observational Study of the Management and Outcomes of Patients with Diabetes during Ramadan (the CREED study) was conducted simultaneously in 13 countries (Table [1](#dme12685-tbl-0001){ref-type="table"}). In each country, physicians involved in the management of Muslim patients with diabetes were selected from the OneKey^®^ database [8](#dme12685-bib-0008){ref-type="ref"}. In countries with limited database representation, local resources were used to solicit physicians' participation. There was no stratification based on specialty or type of practice for physician recruitment.

###### 

The CREED observational study: participation by country of patients with Type 2 diabetes

  Region/Country            Physicians (*N *= 508), *n*   Patients (*N *= 3250), *n*   Overall contribution to study population, %
  ------------------------- ----------------------------- ---------------------------- ---------------------------------------------
  Asia                                                                                 25.1
  India                     31                            271                          8.3
  Indonesia                 66                            259                          8.0
  Malaysia                  32                            286                          8.8
  Europe                                                                               20.7
  France                    39                            139                          4.3
  Germany                   32                            190                          5.8
  UK                        14                            91                           2.8
  Turkey                    24                            252                          7.8
  Middle East                                                                          26.9
  Kingdom of Saudi Arabia   36                            248                          7.6
  Kuwait                    14                            211                          6.5
  United Arab Emirates      33                            417                          12.8
  North Africa                                                                         27.3
  Algeria                   75                            370                          11.4
  Morocco                   61                            282                          8.7
  Tunisia                   51                            234                          7.2
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Physicians were asked to enroll patients with Type 1, Type 2 or gestational diabetes, who were aged ≥ 18 years old on the first day of Ramadan 2010, who were prescribed medication for diabetes, of any type, alone or in combination, and who fasted for any period of time during Ramadan 2010, with at least one documented visit to his/her primary diabetes healthcare practitioner in the 3 calendar months before Ramadan in 2010, and at least one documented visit in the calendar month after Ramadan in 2010. Each participating patient signed an informed consent form before enrolment. The study was approved by the appropriate ethics committees in accordance with local regulations.

Data collection {#dme12685-sec-0007}
---------------

Physician and patient data were collected using standardized questionnaires, translated into the local language if needed. For each patient, data before, during (if a visit occurred) and \< 1 month after Ramadan were gathered from the patient\'s medical records and during a post‐Ramadan face‐to‐face regularly scheduled visit with the physician.

Statistical analyses {#dme12685-sec-0008}
--------------------

Data analyses were performed using [sas]{.smallcaps} ^®^ (Statistical Analysis System, Cary, NC, USA) version 9.2 for Windows. Descriptive statistics including frequency, mean, median, standard deviation and extreme values were determined for continuous variables and absolute and relative frequencies for categorical data. Logistic regressions were performed to determine factors associated with the number of days fasted during Ramadan (\< 15 vs ≥ 15 days), with changes in diabetes treatment regimen during Ramadan, and with occurrence of complications during Ramadan. Univariate analyses were performed to select a first set of covariates to be tested for inclusion in a multivariate model (*P* \< 0.25). The final logistic regression model was obtained by using a backward selection with a threshold level of 0.05.

Results {#dme12685-sec-0009}
=======

A total of 3777 patients were enrolled retrospectively in the study (March to June 2011), for whom 3476 case report forms were received and recorded in the database. After reviewing all forms for minimum data quality requirements, a total of 3394 evaluable cases were used for analysis. Because of inconsistencies between patient demographics, diagnosis and treatment, 82 reported cases were excluded from the analysis (51 patients with gestational diabetes, 30 patients with Type 1 diabetes treated only with oral medication and one patient with Type 2 diabetes with no reported treatment). The Type 2 diabetes subset included 3250 patients (95.8%). Table [2](#dme12685-tbl-0002){ref-type="table"} shows the baseline demographic and clinical characteristics of the studied population. Country‐specific CREED data and outcomes are provided in the Supporting Information (Appendix S1).

###### 

Demographic and clinical features of patients

                                                     Type 2 diabetes
  -------------------------------------------------- -----------------------
  *n*                                                3,250
  Sex: male/female, %                                48.5/51.5
  Mean ± [sd]{.smallcaps} age, years                 56.9 ± 10.7
  Mean ± sd time since diagnosis, years              8.4 ± 6.3
  Mean ± [sd]{.smallcaps} weight, kg                 77.2 ± 15.2
  Mean ± sd BMI, kg/m²                               28.7 ± 5.5
  Mean ± [sd]{.smallcaps} HbA~1c~, mmol/mol (%)      60 ± 17.5 (7.6 ± 1.6)
  Occupation/working status, *n* (%)                 
  Active full‐time worker                            915 (28.3)
  Active part‐time worker                            266 (8.2)
  Non‐active worker                                  709 (21.9)
  Student                                            5 (0.2%)
  Retired                                            810 (25.0)
  Other                                              534 (16.5)
  Diabetes complications, *n* (%)                    
  Neuropathy                                         643 (19.8)
  Retinopathy                                        404 (12.4)
  Nephropathy                                        360 (11.1)
  Coronary artery disease                            334 (10.3)
  Diabetic foot complications                        127 (3.9)
  Peripheral arterial disease                        111 (3.4)
  Cerebrovascular disease                            67 (2.1)
  Comorbidity, *n* (%)                               
  Hypertension                                       2020 (62.1)
  Dyslipidaemia                                      1840 (56.6)
  Physician‐reported risk status (ADA criteria), %   
  Low                                                33.3
  Moderate                                           31.4
  High                                               31.5
  Very high                                          3.8
  Pre‐Ramadan anti‐hyperglycaemic regimens           
  Oral, *n* (%)                                      2490 (76.6)
  Monotherapy, %                                     28.8
  Two‐drug combination, %                            37.7
  Three‐drug combination, %                          9.5
  Injectable only, *n* (%)                           140 (5.1)
  Oral + injectable, *n* (%)                         595 (18.3)

ADA, American Diabetes Association.
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Physician management of diabetes during Ramadan {#dme12685-sec-0010}
-----------------------------------------------

Specific physician approaches to patient education and the use of guidelines are shown in Table [3](#dme12685-tbl-0003){ref-type="table"}. Inter‐country differences in the use of fasting‐specific guidelines were notable, ranging from 28% in France to 88% in Indonesia.

###### 

Physician management of diabetes during Ramadan

                                                                                               Total(*N *= 508), *n* (%)
  -------------------------------------------------------------------------------------------- ---------------------------
  Advice given to fasting patients                                                             
  Missing                                                                                      11
  No                                                                                           19 (3.9)
  Yes                                                                                          478 (96.2)
  If yes,                                                                                      
  Advice given according to type of diabetes:                                                  
  No                                                                                           46 (9.62)
  Yes                                                                                          432 (90.38)
  Advice given according to  medication regimen::                                              
  No                                                                                           39 (8.2)
  Yes                                                                                          439 (91.8)
  Advice given for:                                                                            
  Self‐monitoring of glucose                                                                   389 (81.4)
  Hypoglycaemia                                                                                429 (89.8)
  Hyperglycaemia                                                                               321 (67.2)
  Food intake                                                                                  418 (87.5)
  Other                                                                                        111 (23.2)
  Use of one or more guidelines or recommendations for management of diabetes during Ramadan   318 (62.6)
  If used, specific recommendations[a](#dme12685-note-0003){ref-type="fn"}                     
  ADA 2005 recommendations                                                                     124 (39.0)
  ADA 2010 recommendations                                                                     131 (41.2)
  Local guidelines or recommendations                                                          116 (36.5)
  Other guidelines or recommendations                                                          42 (13.2)
  Use of one or more Ramadan‐focused education programmes                                      342 (67.3)
  If used, specific programmes[a](#dme12685-note-0003){ref-type="fn"}                          
  International                                                                                49 (14.3)
  National                                                                                     106 (31.0)
  Local                                                                                        99 (29.0)
  Provided by pharmaceutical manufacturer                                                      66 (19.3)
  Other                                                                                        67 (19.6)
  If used, education programme is provided by[a](#dme12685-note-0003){ref-type="fn"}           
  One‐on‐one counselling with physician                                                        279 (81.6)
  One‐on‐one counselling with nurse or nurse educator                                          83 (24.3)
  In group sessions                                                                            66 (19.3)
  Via take‐home written material/brochure                                                      130 (38.0)

ADA, American Diabetes Association.

Physicians could specify the use of more than one guideline and education programme.
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Patient demographic and clinical features {#dme12685-sec-0011}
-----------------------------------------

The overall demographic and clinical features of the study population are shown in Table [2](#dme12685-tbl-0002){ref-type="table"}. The population had a mean age of 57 years and had been diagnosed with diabetes for 8.4 years. Three quarters (74.6%) of patients had a documented HbA~1c~ assay in the 3 months before Ramadan: the mean value was 60 mmol/mol (7.6%). The three most prevalent complications of diabetes were neuropathy (19.8%), retinopathy (12.4%) and nephropathy (11.1%). As with previous studies [1](#dme12685-bib-0001){ref-type="ref"}, there was considerable variability between countries and regions. The prevalence of neuropathy ranged from 7.2% in France to 35.5% in Indonesia. The frequency of hypertension (75.5%) and dyslipidaemia (84.9%) was highest in the United Arab Emirates.

Physicians were asked to assess the risk of adverse events for each patient, using American Diabetes Association recommendations [4](#dme12685-bib-0004){ref-type="ref"}. Physicians reported 64.7% of patients to be at low or moderate risk. Again, there was wide variability between countries; physicians in Malaysia reported that only 43.4% of patients could be considered low or moderate risk, while physicians in Germany considered 84.7% of their patients to be in those categories.

Patients were treated with oral antidiabetic drugs alone (76.6%), injectable drugs alone (5.1%), or a combination of an oral antidiabetic drug and an injectable drug (18.3%). Biguanides, alone or in combination, were used by 82.9% of all patients, with monotherapy (17.9%) and combination therapy with a sulphonylurea drug (29.8%) being the most frequent regimens. Patients on injectable drugs alone (all insulin) were prescribed a variety of injection regimens; 8.0% once daily, 54.0% twice daily, 19.7% three times a day and 18.3% four times daily. A total of 23 patients (0.7%) were treated with exenatide or liraglutide, all in combination with another anti‐hyperglycaemic agent.

Diabetes during Ramadan {#dme12685-sec-0012}
-----------------------

Specific lifestyle and treatment changes implemented for Ramadan are shown in Table [4](#dme12685-tbl-0004){ref-type="table"}. Physicians reported a change in diabetes treatment regimens for 39.3% of patients. Irrespective of pre‐Ramadan regimens, changes in frequency of administration (74.8%) were more frequent than changes in total daily dose, or a change in drug, defined as an addition, discontinuation or switch. Treatment regimen changes as a method of managing diabetes during Ramadan varied by country; only 13% of patients in France had changes to their pre‐Ramadan therapy, while 64% of all patients in Kuwait had a treatment change.

###### 

Treatment and diet changes implemented for Ramadan

                                                                           Patients with Type 2 diabetes, *n* (%)   
  ------------------------------------------------------------------------ ---------------------------------------- --------
  Total number of patients                                                 3250                                     
  Patients with changes (overall)[a](#dme12685-note-0005){ref-type="fn"}   1276                                     (39.3)
  Patients on OAD alone (*n *= 2490)                                       869                                      (34.9)
  Patients on injectable therapy alone (*n *= 140)                         66                                       (47.1)
  Patients on injectable + oral therapy (*n *= 595)                        322                                      (54.1)
  Nature of treatment changes, overall study population                                                             
  Number of patients with changes                                          1276                                     
  Change in drug[b](#dme12685-note-0006){ref-type="fn"}                    261                                      (20.4)
  Changes in total daily dose                                              471                                      (36.9)
  Changes in frequency of administration                                   955                                      (74.8)
  Nature of treatment change, patients on OAD only                                                                  
  Number of patients with changes                                          869                                      
  Change in drug[b](#dme12685-note-0006){ref-type="fn"}                    164                                      (18.9)
  Changes in total daily dose                                              278                                      (32.0)
  Changes in frequency of administration                                   635                                      (73.1)
  Nature of treatment changes, patients on injectable therapy alone                                                 
  Number of patients with changes                                          66                                       
  Change in drug[b](#dme12685-note-0006){ref-type="fn"}                    5                                        (7.6)
  Changes in total daily dose                                              31                                       (47.0)
  Changes in frequency of administration                                   55                                       (83.3)
  Nature of treatment changes, patients on injectable + OAD                                                         
  Number of patients with changes                                          322                                      
  Discontinuation of a therapy (OAD or injectable)                         84                                       (26.1)
  Changes in the frequency for administration                              249                                      (77.3)
  Average number of meals consumed each day during Ramadan                                                          
  1                                                                        54                                       (1.7)
  2                                                                        2076                                     (64.1)
  3                                                                        1030                                     (31.8)
  4 or more                                                                79                                       (2.4)
  Change in size of meals                                                  1657                                     (51.7)
  Eat smaller meals                                                        662                                      (40.5)
  Eat larger meals                                                         972                                      (59.5)
  Predominant change in the type of meals                                                                           
  Eat more carbohydrate                                                    1084                                     (61.8)
  Eat more protein                                                         1032                                     (58.9)
  Eat more fat                                                             690                                      (39.4)

OAD, oral antidiabetic drug.

Physicians could assign the change to more than one category.

Change defined as discontinuation of a drug, addition of a drug, switching from one drug to another.
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Fasting practice during Ramadan {#dme12685-sec-0013}
-------------------------------

Table [5](#dme12685-tbl-0005){ref-type="table"} shows the fasting practices both during and outside Ramadan. In all, 94% of patients with Type 2 diabetes in the CREED study reported fasting for at least 15 days during Ramadan. The mean number of fasting days was 27 for the overall study population and ranged from 20.2 (Turkey) to 28.8 days (Saudi Arabia and Algeria). Notably, 30% of patients in the CREED study reported fasting outside of Ramadan, with significant intercountry differences ranging from 8% in India to 46% in Malaysia.

###### 

Patient fasting practice during Ramadan

                                                                                                                      Patients with Type 2 diabetes, *n* (%)
  ------------------------------------------------------------------------------------------------------------------- ----------------------------------------
  Total number of patients, *n* (%)                                                                                   3250
  Patients who fasted every day during Ramadan, *n* (%)                                                               2043 (63.6)
  Mean ± sd overall number of days fasted                                                                             27.2 ± 6.0
  Fasted \< 15 days, *n* (%)                                                                                          187 (5.9)
  Fasted ≥ 15 days, *n* (%)                                                                                           3024 (94.2)
  Fast outside of Ramadan, *n* (%)                                                                                    967 (29.9)
  Mean ± [sd]{.smallcaps} number of days fasted according to ADA risk status[a](#dme12685-note-0008){ref-type="fn"}   
  Low risk                                                                                                            27.3 ± 6.0
  Moderate risk                                                                                                       26.8 ± 6.1
  High risk                                                                                                           27.2 ± 6.0
  Very high risk                                                                                                      24.4 ± 7.9

ADA, American Diabetes Association.

For the overall study population, including 144 patients with Type 1 diabetes.
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Hypoglycaemia and hospitalization during Ramadan {#dme12685-sec-0014}
------------------------------------------------

Patient‐reported episodes of hypoglycaemia during the month of Ramadan and associated severity are reported in Table [6](#dme12685-tbl-0006){ref-type="table"}. During Ramadan, 8.8% of patients reported at least one episode of hypoglycaemia (mean 1.8, range 1--9). Most of the events required either assistance (51.4%) and/or stopping the fast (47.8%). Hospitalization during Ramadan was rare. A total of 15 patients (0.5%) each reported one hospitalization during the month, with only seven of those being related to diabetes.

###### 

Hypoglycaemia during Ramadan

                                                     Patients with Type 2 diabetes
  -------------------------------------------------- -------------------------------
  Total number of patients                           3250
  Patients reporting at least one episode, *n* (%)   285 (8.8)
  Number of episodes of hypoglycaemia, *n* (%)       524
  Mean ± sd                                          1.8 ± 1.3
  Range                                              1--9
  Severity of hypoglycaemia, *n* (%)                 
  Necessitated stopping fast                         249 (47.8)
  Required assistance                                268 (51.4)
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Regression analyses {#dme12685-sec-0015}
-------------------

The results of the logistic regression analyses are shown in Tables [7](#dme12685-tbl-0007){ref-type="table"} and [8](#dme12685-tbl-0008){ref-type="table"}. Fasting for \< 15 days was more likely for patients treated by specialists (vs general practitioners), for women (vs men), patients treated with injectable drugs alone (vs oral antidiabetic drugs alone), for patients with high levels of LDL cholesterol (reference \< 2.5 mmol/l), for patients not given diabetes education (vs those given diabetes education), and for patients with comorbidities before Ramadan (vs those without).

###### 

Logistic regression analysis to determine factors associated with increased risk of fasting \< 15 days

  Variables                           Univariate models   Multivariate model                                                                                                                                                                                                                     
  ----------------------------------- ------------------- -------------------- ------ ---------------- ------------------------------------------------- ------------------------------------------------- ------ ---- ------ ---------------- ------------------------------------------------- -------------------------------------------------
  Type of diabetes                                                                                                                                       \< 0.001[a](#dme12685-note-0010){ref-type="fn"}                                                                                         
  Type 1                              144                 27                   --     --               --                                                                                                                                                                                        
  Type 2                              3250                187                  0.26   \[0.17; 0.41\]   \< 0.001[a](#dme12685-note-0010){ref-type="fn"}                                                                                                                                           
  Specialty of physicians                                                                                                                                0.001[a](#dme12685-note-0010){ref-type="fn"}                                                                                            \< 0.001[a](#dme12685-note-0010){ref-type="fn"}
  General practitioner                1171                50                   --     --               --                                                                                                  389    16   --     --               --                                                 
  Endocrinologist                     305                 27                   1.36   \[0.80; 2.31\]   0.257                                                                                               199    22   4.04   \[1.98; 8.26\]   \< 0.001[a](#dme12685-note-0010){ref-type="fn"}    
  Diabetologist                       489                 33                   0.63   \[0.40; 0.98\]   0.042[a](#dme12685-note-0010){ref-type="fn"}                                                        227    16   2.17   \[1.03; 4.61\]   0.043[a](#dme12685-note-0010){ref-type="fn"}       
  Internist                           823                 71                   1.32   \[0.86; 2.02\]   0.210                                                                                               369    39   2.51   \[1.36; 4.66\]   0.003[a](#dme12685-note-0010){ref-type="fn"}       
  Other                               552                 32                   0.87   \[0.52; 1.43\]   0.572                                                                                               176    7    0.91   \[0.36; 2.32\]   0.846                                              
  Location of the physician site                                                                                                                         0.013[a](#dme12685-note-0010){ref-type="fn"}                                                                                            
  Office‐based                        1877                102                  --     --               --                                                                                                                                                                                        
  Hospital‐based                      1451                111                  1.43   \[1.08; 1.88\]   0.013[a](#dme12685-note-0010){ref-type="fn"}                                                                                                                                              
  Sex of patients                                                                                                                                        0.002[a](#dme12685-note-0010){ref-type="fn"}                                                                                            0.006[a](#dme12685-note-0010){ref-type="fn"}
  Male                                1647                81                   --     --               --                                                                                                  684    38   --     --               --                                                 
  Female                              1733                131                  1.58   \[1.18; 2.10\]   0.002[a](#dme12685-note-0010){ref-type="fn"}                                                        676    62   1.85   \[1.19; 2.86\]   0.006[a](#dme12685-note-0010){ref-type="fn"}       
  Age of patients                                                                                                                                        0.152                                                                                                                                   
  19--49 years                        795                 56                   --     --               --                                                                                                                                                                                        
  49--57 years                        854                 41                   0.67   \[0.44; 1.02\]   0.062                                                                                                                                                                                     
  57--64 years                        861                 54                   0.90   \[0.61; 1.32\]   0.578                                                                                                                                                                                     
  64--96 years                        854                 63                   1.06   \[0.73; 1.53\]   0.775                                                                                                                                                                                     
  BMI                                                                                                                                                    0.087                                                                                                                                   
  ≤ 18.5 kg/m²                        40                  4                    --     --               --                                                                                                                                                                                        
  18.5--25 kg/m²                      748                 64                   0.57   \[0.19; 1.66\]   0.300                                                                                                                                                                                     
  25--30 kg/m²                        1379                84                   0.85   \[0.29; 2.48\]   0.772                                                                                                                                                                                     
  \> 30 kg/m²                         837                 49                   0.59   \[0.21; 1.70\]   0.329                                                                                                                                                                                     
  Diabetes treatment during Ramadan                                                                                                                      \< 0.001[a](#dme12685-note-0010){ref-type="fn"}                                                                                         \< 0.001[a](#dme12685-note-0010){ref-type="fn"}
  OADs alone                          2480                130                  --     --               --                                                                                                  1013   66   --     --               --                                                
  Injectable agents alone             265                 44                   0.28   \[0.19; 0.40\]   \< 0.001[a](#dme12685-note-0010){ref-type="fn"}                                                     93     19   3.87   \[2.13; 7.06\]   \< 0.001[a](#dme12685-note-0010){ref-type="fn"}   
  OADs + injectable agents            582                 37                   0.34   \[0.21; 0.54\]   \< 0.001[a](#dme12685-note-0010){ref-type="fn"}                                                     254    15   0.97   \[0.53; 1.77\]   0.919                                             
  Diabetes education                                                                                                                                     0.006[a](#dme12685-note-0010){ref-type="fn"}                                                                                            \< 0.001[a](#dme12685-note-0010){ref-type="fn"}
  No                                  1129                90                   --     --               --                                                                                                  422    47   --     --               --                                                
  Yes                                 2265                124                  0.67   \[0.51; 0.89\]   0.006[a](#dme12685-note-0010){ref-type="fn"}                                                        938    53   0.40   \[0.25; 0.64\]   \< 0.001[a](#dme12685-note-0010){ref-type="fn"}   
  Time from diagnosis, years          3045                196                  1.00   \[0.97; 1.02\]   0.756                                             0.756                                                                                                                                   
  Blood pressure before Ramadan                                                                                                                          0.074                                                                                                                                   
  Normal                              351                 30                   --     --               --                                                                                                                                                                                        
  Prehypertension                     1613                99                   0.70   \[0.46; 1.07\]   0.099                                                                                                                                                                                     
  Stage 1 hypertension                906                 46                   0.57   \[0.35; 0.92\]   0.021[a](#dme12685-note-0010){ref-type="fn"}                                                                                                                                              
  Stage 2 hypertension                380                 30                   0.91   \[0.54; 1.54\]   0.729                                                                                                                                                                                     
  LDL cholesterol                                                                                                                                        \< 0.001[a](#dme12685-note-0010){ref-type="fn"}                                                                                         0.002[a](#dme12685-note-0010){ref-type="fn"}
  \< 2.5 mmol/l                       552                 17                   --     --               --                                                                                                  430    16   --     --               --                                                
  ≥ 2.5 mmol/l                        1142                95                   2.84   \[1.68; 4.81\]   \< 0.001[a](#dme12685-note-0010){ref-type="fn"}                                                     930    84   2.43   \[1.38; 4.27\]   0.002[a](#dme12685-note-0010){ref-type="fn"}      
  HDL cholesterol                                                                                                                                        0.396                                                                                                                                   
  \< 1 mmol/l                         486                 28                   --     --               --                                                                                                                                                                                        
  ≥ 1 mmol/l                          1187                82                   1.21   \[0.78; 1.89\]   0.396                                                                                                                                                                                     
  Triglycerides                                                                                                                                          0.003[a](#dme12685-note-0010){ref-type="fn"}                                                                                            
  \< 2.5 mmol/l                       1798                99                   --     --               --                                                                                                                                                                                        
  ≥ 2.5 mmol/l                        409                 39                   1.80   \[1.22; 2.65\]   0.003[a](#dme12685-note-0010){ref-type="fn"}                                                                                                                                              
  Comorbidities before Ramadan                                                                                                                           0.035[a](#dme12685-note-0010){ref-type="fn"}                                                                                            0.033[a](#dme12685-note-0010){ref-type="fn"}
  No                                  554                 46                   --     --               --                                                                                                  214    24   --     --               --                                                
  Yes                                 2840                168                  0.69   \[0.49; 0.97\]   0.035[a](#dme12685-note-0010){ref-type="fn"}                                                        1146   76   0.57   \[0.34; 0.96\]   0.033[a](#dme12685-note-0010){ref-type="fn"}      

OR, odds ratio.

*P* ≤ 0.05.

Number of patients who fasted for \< 15 days during Ramadan.
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###### 

Logistic regression analysis to determine factors associated with changes in diabetes treatment regimen during Ramadan

                                      Univariate models   Multivariate model                                                                                                                                                                                                                      
  ----------------------------------- ------------------- -------------------- ------ ---------------- ------------------------------------------------- ------------------------------------------------- ------ ----- ------ ---------------- ------------------------------------------------- -------------------------------------------------
  Type of diabetes                                                                                                                                       \< 0.001[a](#dme12685-note-0013){ref-type="fn"}                                                                                          0.036[a](#dme12685-note-0013){ref-type="fn"}
  Type 1                              144                 72                   --     --               --                                                                                                  91     48    --     --               --                                                 
  Type 2                              3250                994                  0.44   \[0.32; 0.62\]   \< 0.001[a](#dme12685-note-0013){ref-type="fn"}                                                     2008   629   0.56   \[0.33; 0.96\]   0.036[a](#dme12685-note-0013){ref-type="fn"}       
  Specialty of physicians                                                                                                                                0.016[a](#dme12685-note-0013){ref-type="fn"}                                                                                             0.019[a](#dme12685-note-0013){ref-type="fn"}
  General practitioner                1171                351                  --     --               --                                                                                                  646    190   --     --               --                                                
  Endocrinologist                     305                 105                  0.98   \[0.81; 1.19\]   0.829                                                                                               254    85    1.07   \[0.77; 1.47\]   0.698                                             
  Diabetologist                       489                 150                  1.38   \[1.12; 1.71\]   0.003[a](#dme12685-note-0013){ref-type="fn"}                                                        368    109   0.90   \[0.67; 1.20\]   0.454                                             
  Internist                           823                 243                  1.03   \[0.82; 1.30\]   0.777                                                                                               501    162   1.12   \[0.87; 1.45\]   0.388                                             
  Other                               552                 205                  1.23   \[0.94; 1.60\]   0.134                                                                                               330    131   1.51   \[1.13; 2.01\]   0.005[a](#dme12685-note-0013){ref-type="fn"}      
  Location of the physician site                                                                                                                         0.480                                                                                                                                    
  Office‐based                        1877                605                  --     --               --                                                                                                                                                                                         
  Hospital‐based                      1451                451                  0.95   \[0.82; 1.10\]   0.480                                                                                                                                                                                      
  Sex of patients                                                                                                                                        0.767                                                                                                                                    
  Male                                1647                521                  --     --               --                                                                                                                                                                                         
  Female                              1733                540                  0.98   \[0.85; 1.13\]   0.767                                                                                                                                                                                      
  Age of patients                                                                                                                                        0.233                                                                                                                                    
  19--49 years                        795                 241                  --     --               --                                                                                                                                                                                         
  49--57 years                        854                 248                  0.94   \[0.76; 1.16\]   0.571                                                                                                                                                                                      
  57--64 years                        861                 281                  1.11   \[0.90; 1.37\]   0.310                                                                                                                                                                                      
  64--96 years                        854                 282                  1.13   \[0.92; 1.40\]   0.238                                                                                                                                                                                      
  BMI                                                                                                                                                    0.131                                                                                                                                    0.026[a](#dme12685-note-0013){ref-type="fn"}
  ≤ 18.5 kg/m²                        40                  16                   --     --               --                                                                                                  19     11    --     --               --                                                 
  18.5--25 kg/m²                      748                 266                  0.68   \[0.36; 1.30\]   0.244                                                                                               499    177   0.41   \[0.16; 1.07\]   0.068                                              
  25--30 kg/m²                        1379                433                  0.83   \[0.43; 1.59\]   0.569                                                                                               976    306   0.35   \[0.13; 0.91\]   0.031[a](#dme12685-note-0013){ref-type="fn"}       
  \> 30 kg/m²                         837                 261                  0.69   \[0.36; 1.31\]   0.251                                                                                               605    183   0.31   \[0.12; 0.80\]   0.016[a](#dme12685-note-0013){ref-type="fn"}       
  Diabetes treatment before Ramadan                                                                                                                      \< 0.001[a](#dme12685-note-0013){ref-type="fn"}                                                                                          \< 0.001[a](#dme12685-note-0013){ref-type="fn"}
  ‐ OADs alone                        2490                691                  --     --               --                                                                                                  1515   420   --     --               --                                                 
  Injectable agents alone             246                 93                   0.63   \[0.48; 0.83\]   \< 0.001[a](#dme12685-note-0013){ref-type="fn"}                                                     166    69    1.26   \[0.83; 1.91\]   0.273                                              
  OADs +injectable agents             632                 274                  1.26   \[0.93; 1.70\]   0.135                                                                                               418    188   1.92   \[1.51; 2.43\]   \< 0.001[a](#dme12685-note-0013){ref-type="fn"}    
  Diabetes education                                                                                                                                     0.323                                                                                                                                    
  No                                  1129                342                  --     --               --                                                                                                                                                                                         
  Yes                                 2265                724                  1.08   \[0.93; 1.26\]   0.323                                                                                                                                                                                      
  Time from diagnosis, years          3079                957                  1.02   \[1.01; 1.03\]   \< 0.001[a](#dme12685-note-0013){ref-type="fn"}   \< 0.001[a](#dme12685-note-0013){ref-type="fn"}                                                                                          
  Blood pressure before Ramadan                                                                                                                          0.059                                                                                                                                    
  Normal                              351                 100                  --     --               --                                                                                                                                                                                         
  Prehypertension                     1613                510                  1.16   \[0.90; 1.50\]   0.251                                                                                                                                                                                      
  Stage 1 hypertension                906                 281                  1.13   \[0.86; 1.48\]   0.382                                                                                                                                                                                      
  Stage 2 hypertension                380                 142                  1.50   \[1.10; 2.04\]   0.011[a](#dme12685-note-0013){ref-type="fn"}                                                                                                                                               
  HbA~1c~                                                                                                                                                \< 0.001[a](#dme12685-note-0013){ref-type="fn"}                                                                                          0.002[a](#dme12685-note-0013){ref-type="fn"}
  \< 48 mmol/mol (6.5%)               431                 111                  --     --               --                                                                                                  358    93    --     --               --                                                 
  48--64 mmol/mol (6.5--8%)           1269                375                  1.79   \[1.39; 2.32\]   \< 0.001[a](#dme12685-note-0013){ref-type="fn"}                                                     1078   325   1.19   \[0.90; 1.56\]   0.218                                              
  \> 64 mmol/mol (8%)                 827                 317                  1.21   \[0.94; 1.55\]   0.132                                                                                               663    259   1.60   \[1.19; 2.15\]   0.002[a](#dme12685-note-0013){ref-type="fn"}       
  LDL cholesterol                                                                                                                                        0.274                                                                                                                                    
  \< 2.5 mmol/l                       552                 161                  --     --               --                                                                                                                                                                                         
  ≥ 2.5 mmol/l                        1142                363                  1.13   \[0.91; 1.41\]   0.274                                                                                                                                                                                      
  HDL cholesterol                                                                                                                                        0.373                                                                                                                                    
  \< 1 mmol/L                         486                 154                  --     --               --                                                                                                                                                                                         
  ≥ 1 mmol/L                          1187                350                  0.90   \[0.72; 1.13\]   0.373                                                                                                                                                                                      
  Triglycerides                                                                                                                                          0.655                                                                                                                                    
  \< 2.5 mmol/l                       1798                560                  --     --               --                                                                                                                                                                                         
  ≥ 2.5 mmol/l                        409                 132                  1.05   \[0.84; 1.33\]   0.655                                                                                                                                                                                      
  Comorbidities before Ramadan                                                                                                                           0.841                                                                                                                                    
  No                                  554                 176                  --     --               --                                                                                                                                                                                         
  Yes                                 2840                890                  0.98   \[0.81; 1.19\]   0.841                                                                                                                                                                                      

OR, odds ratio.

*P* ≤ 0.05.

Number of patients with changes in diabetes treatment regimen during Ramadan.

John Wiley & Sons, Ltd

A change in diabetes treatment regimen during Ramadan was more likely for patients being treated by other specialists (vs general practitioner), patients with a BMI \> 25 kg/m^2^ (vs ≤ 18.5 kg/m^2^), patients on an injectable plus oral regimen (vs an oral antidiabetic drug alone) and patients with a pre‐Ramadan HbA~1c~ level \> 64 mmol/mol (8%) \[vs \< 48 mmol/mol (6.5%)\].

There were no identifiable factors associated with the occurrence of complications during Ramadan.

Discussion {#dme12685-sec-0016}
==========

The CREED study provides an important update on the characteristics and management of patients with diabetes who chose to fast during Ramadan in 2010. The CREED study was not meant to replicate the landmark EPIDIAR study in either design or conduct. The two studies have notable differences, and comparison of results between the studies has limitations. To provide the present update, however, it was necessary to compare the results of the studies and report and discuss the differences observed.

While the EPIDIAR study focused on countries with predominantly Muslim populations from East/North Africa, the Middle East and Asia‐Pacific countries, the CREED study also included European patients in countries with minority Muslim populations. The two studies were conducted in seven common countries.

The age of patients and time since diagnosis were similar in the two studies, 56.9 vs 54.0 years and 8.4 vs 7.6 years in the CREED and EPIDIAR studies, respectively. Patients in the CREED study presented with a higher BMI (28.7 vs 27.2 kg/m^2^). The proportion of patients with Type 2 diabetes was slightly higher in the CREED than in the EPIDIAR study (95.8 vs 91.3%), perhaps because of the increasing prevalence of Type 2 diabetes [9](#dme12685-bib-0009){ref-type="ref"}, but perhaps also because of a difference in the age structure of targeted countries, which might have been influenced by the inclusion of European countries with older populations. Additionally, this could be a consequence of the CREED study inclusion criteria, whereby a greater proportion of patients with Type 2 diabetes intended to fast, compared with patients with Type 1 diabetes.

The three most frequent diabetes complications were the same for both studies, but the overall prevalence of each complication was lower in the CREED study (neuropathy, 19.8 vs 27.8%; retinopathy, 12.4 vs 19.7%; nephropathy, 11.1 vs 12.1%). The prevalence of two common comorbidities was higher in the CREED study (hypertension, 62.1 vs 48.8%; dyslipidaemia, 56.6 vs 32.5%). The lower prevalence of complications observed in the present cohort may be explained by changes in the management of patients with diabetes since the EPIDIAR study was conducted, but the bias introduced by the inclusion of countries with differential access to newer medications must also be considered.

To our knowledge, we are the first to report on physicians' perception of the risk of adverse events in patients with diabetes who fast during Ramadan. As noted earlier, an interesting finding was that there appears to be inter‐country and perhaps regional differences in physician‐perceived risk. In general, physicians in Europe reported a higher percentage of patients in the low‐ and medium‐risk category (ranging from 64.9% in the UK to 84.8% in Germany) than physicians in Asia (ranging from 43.4% in Malaysia to 79.1% Indonesia). This might be explained by differences in baseline treatment regimens; for example, there was much higher use of sulphonylurea drugs in Malaysia (61.2% of all patients) compared with Germany (20.0% of patients); however, other factors, including the number and extent of baseline risk factors, may explain the difference.

The use of fasting‐specific advice appears to have greatly increased. In all, 96% of investigators in the CREED study reported providing fasting‐specific advice concerning self‐care, in line with American Diabetes Association recommendations for pre‐Ramadan educational counselling. When specific guidelines were referenced, \~ 40% of physicians reported using the American Diabetes Association 2005 and/or American Diabetes Association 2010 recommendations, which were not available to EPIDIAR investigators. By comparison, physicians in the EPIDIAR study reported that 62% of patients with Type 2 diabetes were provided with fasting‐ and diabetes‐specific guidelines.

Oral anti‐hyperglycaemic therapy alone was the predominant baseline therapy in the CREED study (76.6%), similar to that in the EPIDIAR study (78.4%); however, the use of oral monotherapy has decreased, while the use of two or more oral drugs in combination has increased, reflective of modern diabetes management. Approximately 25% of patients in the EPIDIAR study changed their pre‐Ramadan oral anti‐hyperglycaemic dose, while 35% of patients in the CREED study on oral therapy alone had a change in dose or frequency before Ramadan. Similarly, 35.9% of patients in the EPIDIAR study experienced some change in insulin dose, while \~ 50% of patients in the CREED study who were on injectable therapies had a change to their baseline regimen. Regardless of baseline therapy, when changes in pre‐Ramadan regimens did occur, they were most often changes in period of administration, consistent with American Diabetes Association recommendations.

A total of 94% of patients in the CREED study reported fasting for ≥ 15 days during Ramadan, compared with 78.7% of patients in the EPIDIAR study. We have previously noted the many changes that have occurred since 2001 that certainly may have influenced the ability of a patient to complete his/her fast, but are unable to establish a causal relationship with any specific change.

We also believe we are the first to report on the extent of non‐obligatory fasting outside of Ramadan. Notably, 30% of patients in the CREED study reported fasting outside of Ramadan, with significant inter‐country differences ranging from 8% in India to 46% in Malaysia. It is important to note that a large number of patients fast frequently throughout the year and this should potentially be considered in ongoing patient management and treatment selection.

When compared with recent studies [10](#dme12685-bib-0010){ref-type="ref"}, [11](#dme12685-bib-0011){ref-type="ref"}, [12](#dme12685-bib-0012){ref-type="ref"}, the incidence of patient‐reported hypoglycaemia in the CREED study during the month of Ramadan was low: 8.8% of patients reported at least one episode. Notably, however, these were prospective, often diary‐based studies, primarily focused on event rates associated with sulphonylurea use, with or without a comparison with hypoglycaemia event rates associated with the use of dipeptidyl peptidase‐4 inhibitors. Reported rates for hypoglycaemia ranged from 0.0 to 6.7% for dipeptidyl peptidase‐4 inhibitors and from 13.2 to 41.7% for sulphonylurea therapy [10](#dme12685-bib-0010){ref-type="ref"}, [12](#dme12685-bib-0012){ref-type="ref"}. A more appropriate comparison might be made with a prospective observational study that also examined the role of drug therapy change, glucose monitoring and patient education on acute diabetic complications in patients with diabetes fasting during the month of Ramadan [13](#dme12685-bib-0013){ref-type="ref"}. The authors reported a symptomatic hypoglycaemia rate of 6.36% and either improvement or non‐deterioration in glycaemic control with fasting. In the CREED study, 61.2% of patients had a recorded HbA~1c~ value in the post‐Ramadan period: the mean was 58 mmol/mol (7.5%), which was similar to the pre‐Ramadan mean of 60 mmol/mol (7.6%). Together, these two studies provide encouraging data to suggest that, with appropriate multiple‐approach management, the majority of patients with diabetes who choose to fast during Ramadan can safely fast for the majority, if not all, of the month.

The present study has several limitations. The data are derived from a convenience sample of largely urban physician practices and included only patients with a physician visit both before and after Ramadan 2010. No data were collected on the characteristics and outcomes associated with patients who chose to fast but did not present to a healthcare professional before fasting. The retrospective observational design of the study is subject to recall bias and does not allow causal inferences. This might particularly affect the validity of patient‐reported hypoglycaemia; however, we would argue that this bias is somewhat mitigated when looking specifically at hypoglycaemic episodes during Ramadan. In this case, patients may be acutely aware of past events, particularly those which required a break in fasting, as they would be required to compensate for the broken fast after Ramadan.

The present study provided an important update on the characteristics and management of patients with diabetes who chose to fast during Ramadan. Despite religious and medical guidance that may otherwise exempt some from the obligation to fast, a large number of Muslim patients will attempt to fast. A large number of patients can and do fast the majority, if not all, of the month of Ramadan. Nevertheless, we have identified variable uptake of methods of assisting in the management of these patients between individual countries. Identifying and removing barriers to uptake may allow even more patients to fast safely. In addition, there is some evidence to suggest that physicians may have different perceptions of the potential risk associated with prolonged fasting. Lastly, there is a large number of patients with diabetes who fast in a non‐obligatory or intermittent fashion, again with much difference between countries.

There is still a need to explore physician and patient perceptions and practices to inform the evidence‐based management of diabetes during fasting, both prolonged and intermittent, and to identify and address barriers to the universal uptake of methods to help manage those patients. We would encourage the use of clinical and/or well‐designed prospective, observational trials to address these needs.
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